Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | PTAFR | P25105 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20561706 | 1.00 | MET (0.41) | METSTAT3PTAFRHSD11B1PTPN1 | |
| SCHEMBL9492727 | 1.00 | MET (0.41) | METSTAT3PTAFRHSD11B1PTPN1 | |
| SCHEMBL20561597 | 1.00 | MET (0.41) | METSTAT3PTAFRHSD11B1PTPN1 | |
| SCHEMBL945693 | 1.00 | MET (0.41) | METSTAT3PTAFRHSD11B1PTPN1 | |
| SCHEMBL2197973 | 0.88 | PTAFR (0.35) | PTAFRHSD11B1 | |
| SCHEMBL2198033 | 0.88 | PTAFR (0.35) | PTAFRHSD11B1 | |
| SCHEMBL2196499 | 0.88 | PTAFR (0.35) | PTAFRHSD11B1 | |
| SCHEMBL20561653 | 0.83 | MET (0.35) | MET | |
| SCHEMBL2193918 | 0.83 | MET (0.35) | MET | |
| SCHEMBL20561463 | 0.83 | MET (0.42) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977384-B1 | Anticancer tobacco cembranoids | THE UNIVERSITY OF LOUISIANA AT MONROE (US) | 2011-07-12 | — | — | US | claimed |
| US-6489357-B1 | ADMINISTERING CEMBRANOIDS TO A LIVING HOST REDUCES SENSITIZATION TO NICOTINE; THESE INCLUDE EUNICIN, EUPALMERIN ACETATE, 12,13-BISEPIEUPALMERIN, 4S-CEMBRATRIENE AND 4R-CEMBRATRIENE | UNIVERSITY OF PUERTO RICO | 2002-12-03 | — | — | US | claimed |
| EP-0200790-B1 | ANTINEOPLASTIC AGENT | Japan Tobacco Inc. (JP) | 1990-09-26 | — | — | EP | claimed |
| US-4701570-A | Antitumor agent | JAPAN TOBACCO INC. (JP) | 1987-10-20 | — | — | US | claimed |
| EP-0200790-A1 | ANTINEOPLASTIC AGENT | Japan Tobacco Inc. (JP) | 1986-11-12 | — | — | EP | claimed |
| US-9278078-B2 | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors | FERCHMIN PETER ANDREW (US) | 2016-03-08 | — | — | US | disclosed |
| US-9259400-B2 | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors | FERCHMIN PETER ANDREW (US) | 2016-02-16 | — | — | US | disclosed |
| US-9259411-B2 | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors | FERCHMIN PETER ANDREW (US) | 2016-02-16 | — | — | US | disclosed |
| US-20160008299-A1 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS | FERCHMIN PETER ANDREW (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160008315-A1 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS | FERCHMIN PETER ANDREW (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160000729-A1 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS | FERCHMIN PETER ANDREW (US) | 2016-01-07 | — | — | US | disclosed |
| US-9000030-B2 | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors | FERCHMIN PETER ANDREW (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130165495-A1 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS | FERCHMIN PETER ANDREW (US) | 2013-06-27 | — | — | US | disclosed |
| US-7977384-B1 | Anticancer tobacco cembranoids | THE UNIVERSITY OF LOUISIANA AT MONROE (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110015186-A1 | METHODS AND COMPOSITIONS FOR PROTECTING AND TREATING NEUROINJURY | MOREHOUSE SCHOOL OF MEDICINE (US) | 2011-01-20 | — | — | US | disclosed |
| US-20090291976-A1 | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors | NEUROPROTECTION FOR LIFE CORP. (PR) | 2009-11-26 | — | — | US | disclosed |
| US-6489357-B1 | ADMINISTERING CEMBRANOIDS TO A LIVING HOST REDUCES SENSITIZATION TO NICOTINE; THESE INCLUDE EUNICIN, EUPALMERIN ACETATE, 12,13-BISEPIEUPALMERIN, 4S-CEMBRATRIENE AND 4R-CEMBRATRIENE | UNIVERSITY OF PUERTO RICO | 2002-12-03 | — | — | US | disclosed |
| EP-0200790-B1 | ANTINEOPLASTIC AGENT | Japan Tobacco Inc. (JP) | 1990-09-26 | — | — | EP | disclosed |
| US-4701570-A | Antitumor agent | JAPAN TOBACCO INC. (JP) | 1987-10-20 | — | — | US | disclosed |
| EP-0200790-A1 | ANTINEOPLASTIC AGENT | Japan Tobacco Inc. (JP) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165495-A1 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS | CHRNA7, CHRNA4, CHRNA10 | MET 4416/4885STAT3 2268/4885PTAFR 3011/4885 |
| US-20160008315-A1 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS | CHRNA7, CHRNA4, CHRNA10 | MET 4339/4885STAT3 2203/4885PTAFR 3303/4885 |
| US-20160000729-A1 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS | CHRNA7, CHRNA4, CHRNA10 | MET 4416/4885STAT3 2268/4885PTAFR 3011/4885 |
| US-20160008299-A1 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS | CHRNA7, CHRNA4, CHRNA10 | MET 4416/4885STAT3 2268/4885PTAFR 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.